## Kirsten L Viola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7115167/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease. Nature Communications, 2022, 13, 159.	12.8	42
2	An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis. International Journal of Molecular Sciences, 2022, 23, 2208.	4.1	5
3	Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer's patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathology and Applied Neurobiology, 2021, 47, 488-505.	3.2	25
4	The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 768646.	2.8	10
5	Aβ oligomer induced cognitive impairment and evaluation of ACU193â€MNSâ€based MRI in rabbit. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12087.	3.7	4
6	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	2.4	46
7	The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	2.6	572
8	A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloidâ€Î² oligomers. Journal of Neurochemistry, 2017, 142, 934-947.	3.9	27
9	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers. Molecular Biology of the Cell, 2017, 28, 2623-2636.	2.1	88
10	P4-177: An ultrasensitive immunoassay detects soluble AÎ <sup>2</sup> oligomers in tg mice prior to memory loss. , 2015, 11, P847-P847.		0
11	Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica, 2015, 129, 183-206.	7.7	490
12	Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nature Nanotechnology, 2015, 10, 91-98.	31.5	155
13	Elucidating Molecular Mass and Shape of a Neurotoxic AÎ <sup>2</sup> Oligomer. ACS Chemical Neuroscience, 2014, 5, 1238-1245.	3.5	24
14	Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-β Oligomer Antibody in 5XFAD Mice. Journal of Alzheimer's Disease, 2013, 35, 777-788.	2.6	56
15	Synapse-Binding Subpopulations of $A^2$ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies. ACS Chemical Neuroscience, 2012, 3, 972-981.	3.5	45
16	Insights into the mechanism of Alzheimer's β-amyloid aggregation as a function of concentration by using atomic force microscopy. Applied Physics Letters, 2012, 100, .	3.3	7
17	Soluble state high resolution atomic force microscopy study of Alzheimer's β-amyloid oligomers. Applied Physics Letters, 2009, 95, 183701.	3.3	17
18	Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1971-1976.	7.1	592

KIRSTEN L VIOLA

#	Article	IF	CITATIONS
19	Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins. CNS and Neurological Disorders - Drug Targets, 2009, 8, 65-81.	1.4	29
20	Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease. Journal of Neuroscience, 2007, 27, 796-807.	3.6	1,090
21	AÎ <sup>2</sup> Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine. Journal of Biological Chemistry, 2007, 282, 11590-11601.	3.4	769
22	Monoclonal antibodies that target pathological assemblies of Aβ. Journal of Neurochemistry, 2007, 100, 23-35.	3.9	308
23	Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers. Journal of Neuroscience, 2004, 24, 10191-10200.	3.6	905
24	Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10417-10422.	7.1	995
25	Self-Assembly of Aβ <sub>1</sub> <sub>-</sub> 42into Globular Neurotoxins. Biochemistry, 2003, 42, 12749-12760.	2.5	511
26	Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Research, 2002, 924, 133-140.	2.2	515
27	Vaccination with soluble Al̂² oligomers generates toxicityâ€neutralizing antibodies. Journal of Neurochemistry, 2001, 79, 595-605.	3.9	309